Immune Support Peptides: Structural Diversity Drives Bioactivity
Published: July 14, 2026 20:08
Author: Chiara Nguyen
Abstract: Immune support peptides exhibit structure-dependent bioactivity, driving market expansion projected at 8.9% CAGR (2024–2030). Comparative analysis of leading brands (e.g., BioPeptin vs. ImmunoGuard) reveals trade-offs: higher purity (≥98% HPLC) correlates with enhanced efficacy but increased cost. Key parameters—molecular weight (<1 kDa), chain length (2–10 amino acids), and solubility—determine absorption. Regulatory compliance (FDA GRAS, EU Novel Food) is critical for product legitimacy. Selection criteria prioritize third-party testing (ISO 17025) and cold-chain logistics (2–8°C) to preserve stability. Current industry fragmentation underscores demand for standardized quality benchmarks.